Search Results

Impact of rat P450 genetic polymorphism on diazepam metabolism

Authors: Sakai, Noriaki; Ishizuka, Mayumi

Source: Expert Opinion on Drug Metabolism and Toxicology, Volume 5, Number 11, November 2009 , pp. 1421-1433(13)

Publisher: Informa Healthcare

Interactions Between Herbal Medicines and Prescribed Drugs: An Updated Systematic Review

Authors: Izzo, Angelo A.; Ernst, Edzard

Source: Drugs, Volume 69, Number 13, 10 September 2009 , pp. 1777-1798(22)

Publisher: Adis International

Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity

Authors: LLerena, Adrián; Dorado, Pedro; Peñas-Lledó, Eva M

Source: Pharmacogenomics, Volume 10, Number 1, January 2009 , pp. 17-28(12)

Publisher: Future Medicine

Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers

Authors: González, Idilio; Peñas-Lledó, Eva M; Pérez, Bárbaro; Dorado, Pedro; Álvarez, Mayra; LLerena, Adrián

Source: Pharmacogenomics, Volume 9, Number 7, July 2008 , pp. 833-840(8)

Publisher: Future Medicine

Genotyping of the cytochrome P450 2D6 4469 C>T polymorphism using SimpleProbes™

Authors: Nielsen, K. A.; Hansen, E. Lyders; Gille, S.

Source: Scandinavian Journal of Clinical and Laboratory Investigation, Volume 67, Number 3, 2007 , pp. 280-290(11)

Publisher: Informa Healthcare

Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping

Authors: Frank, D.; Jaehde, U.; Fuhr, U.

Source: European Journal of Clinical Pharmacology, Volume 63, Number 4, April 2007 , pp. 321-333(13)

Publisher: Springer

Association of CYP2D6 100 C > T and 2850 C > T polymorphisms with generalized tonic clonic seizures among Indians

Authors: Soundararajan, C. C.; Adhin, A.; Tripathi, M.; Prasad, H. K.; Jain, S.; Vivekanandhan, S.

Source: Journal of Neural Transmission, Volume 113, Number 12, December 2006 , pp. 1873-1876(4)

Publisher: Springer

Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

Authors: Wennerholm, Agneta; Nordmark, Anna; Pihlsgård, Maria; Mahindi, Margarita; Bertilsson, Leif; Gustafsson, Lars

Source: European Journal of Clinical Pharmacology, Volume 62, Number 7, July 2006 , pp. 539-546(8)

Publisher: Springer

Clinical Assessment of Effects of Botanical Supplementation on Cytochrome P450 Phenotypes in the Elderly: St John’s Wort, Garlic Oil, Panax ginseng and Ginkgo biloba

Authors: Gurley, Bill J.; Gardner, Stephanie F.; Hubbard, Martha A.; Williams, D. Keith; Gentry, W. Brooks; Cui, Yanyan; Ang, Catharina Y.W.

Source: Drugs & Aging, Volume 22, Number 6, 2005 , pp. 525-539(15)

Publisher: Adis International

Parkinson's disease risk factors: genetic, environmental, or both?

Authors: Allam, Mohamed Farouk; Del Castillo, Amparo Serrano; Navajas, Rafael Fernández-Crehuet

Source: Neurological Research, Volume 27, Number 2, March 2005 , pp. 206-208(3)

Publisher: Maney Publishing

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

Authors: Zanger, Ulrich; Raimundo, Sebastian; Eichelbaum, Michel

Source: Naunyn-Schmiedeberg's Archives of Pharmacology, Volume 369, Number 1, January 2004 , pp. 23-37(15)

Publisher: Springer

Fatal intoxication cases: cytochrome P ₄₅₀ 2D6 and 2C19 genotype distributions

Authors: Zackrisson, A.; Holmgren, P.; Gladh, A.; Ahlner, J.; Lindblom, B.

Source: European Journal of Clinical Pharmacology, Volume 60, Number 8, October 2004 , pp. 547-552(6)

Publisher: Springer

Genetic Predictors of the Clinical Response to Opioid Analgesics: Clinical Utility and Future Perspectives

Authors: Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger

Source: Clinical Pharmacokinetics, Volume 43, Number 14, 2004 , pp. 983-1013(31)

Publisher: Adis International

The Role of Cytochrome P450 Enzymes in the Metabolism of Risperidone and Its Clinical Relevance for Drug Interactions

Authors: R. Berecz; P. Dorado; A. D.L. Rubia; M. C. Caceres; I. Degrell; A. LLerena

Source: Current Drug Targets, Volume 5, Number 6, August 2004 , pp. 573-579(7)

Publisher: Bentham Science Publishers

Relationship between Type A and B personality and debrisoquine hydroxylation capacity

Authors: Gan S.H.; Ismail R.; Wan Adnan W.A.; Zulmi W.; Kumaraswamy N.; Larmie E.T.

Source: British Journal of Clinical Pharmacology, Volume 57, Number 6, June 2004 , pp. 785-789(5)

Publisher: Blackwell Publishing

Pharmacokinetic and pharmacodynamic assessment of a five-probe metabolic cocktail for CYPs 1A2, 3A4, 2C9, 2D6 and 2E1

Authors: Blakey G.E.; Lockton J.A.; Perrett J.; Norwood P.; Russell M.; Aherne Z.; Plume J.

Source: British Journal of Clinical Pharmacology, Volume 57, Number 2, February 2004 , pp. 162-169(8)

Publisher: Blackwell Publishing

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication

Author: Cascorbi, I.

Source: European Journal of Clinical Investigation, Volume 33, Supplement 2, November 2003 , pp. 17-22(6)

Publisher: Blackwell Publishing

Overexpression of CYP2D6 Attenuates the Toxicity of MPP^&Thorn;pl in Actively Dividing and Differentiated PC12 Cells

Authors: MATOH N.; TANAKA S.; TAKEHASHI M.; BANASIK M.; STEDEFORD T.; MASLIAH E.; SUZUKI S.; NISHIMURA Y.; UEDA K.

Source: Gene Expression, Volume 11, Numbers 3-4, 2003 , pp. 117-124(8)

Publisher: Cognizant Communication Corporation

CYP1A1 and CYP2D6 polymorphism and risk of lung cancer in a North Indian population

Authors: C. Sobti R.; Sharma S.; Joshi A.; K. Jindal S.; Janmeja A.

Source: Biomarkers, Volume 8, Number 5, October 2003 , pp. 415-428(14)

Publisher: Informa Healthcare

The Hepatic and Intestinal Metabolic Activities of P450 in Rats with Surgery- and Drug-Induced Renal Dysfunction

Authors: Okabe H.; Hasunuma M.; Hashimoto Y.

Source: Pharmaceutical Research, Volume 20, Number 10, October 2003 , pp. 1591-1594(4)

Publisher: Springer